US Bancorp’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-54
| Closed | -$4K | – | 4357 |
|
|
2022
Q3 | $4K | Buy |
54
+10
| +23% | +$551 | ﹤0.01% | 3700 |
|
|
2022
Q2 | $1K | Sell |
44
-359
| -89% | -$10.5K | ﹤0.01% | 4052 |
|
|
2022
Q1 | $14K | Sell |
403
-840
| -68% | -$25.1K | ﹤0.01% | 3267 |
|
|
2021
Q4 | $37K | Sell |
1,243
-142
| -10% | -$4.4K | ﹤0.01% | 2811 |
|
|
2021
Q3 | $36K | Buy |
1,385
+478
| +53% | +$14.1K | ﹤0.01% | 2827 |
|
|
2021
Q2 | $32K | Buy |
907
+654
| +258% | +$25.5K | ﹤0.01% | 2897 |
|
|
2021
Q1 | $10K | Sell |
253
-153
| -38% | -$7.03K | ﹤0.01% | 3305 |
|
|
2020
Q4 | $18K | Sell |
406
-1,068
| -72% | -$52.7K | ﹤0.01% | 2971 |
|
|
2020
Q3 | $81K | Buy |
1,474
+36
| +3% | +$2.29K | ﹤0.01% | 2192 |
|
|
2020
Q2 | $91K | Buy |
1,438
+693
| +93% | +$47.5K | ﹤0.01% | 2161 |
|
|
2020
Q1 | $38K | Sell |
745
-11
| -1% | -$737 | ﹤0.01% | 2478 |
|
|
2019
Q4 | $60K | Buy |
756
+745
| +6,773% | +$44.1K | ﹤0.01% | 2393 |
|
|
2019
Q3 | $1K | Buy |
+11
| New | +$573 | ﹤0.01% | 3540 |
|
|
2019
Q2 | – | Sell |
-209
| Closed | -$11K | – | 3710 |
|
|
2019
Q1 | $11K | Sell |
209
-257
| -55% | -$12.6K | ﹤0.01% | 3044 |
|
|
2018
Q4 | $19K | Sell |
466
-529
| -53% | -$19.8K | ﹤0.01% | 2838 |
|
|
2018
Q3 | $38K | Hold |
995
| – | – | ﹤0.01% | 2692 |
|
|
2018
Q2 | $45K | Buy |
+995
| New | +$45.3K | ﹤0.01% | 2631 |
|
|
2018
Q1 | – | Sell |
-162
| Closed | -$6K | – | 3730 |
|
|
2017
Q4 | $6K | Buy |
+162
| New | +$6.05K | ﹤0.01% | 3295 |
|
Other funds holding GBT
US Bancorp's GBT Position: Q4 2022 in Review
US Bancorp sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 54 shares — an estimated $4K sold.
US Bancorp first reported a position in GBT in Q4 2017 and held it in 18 quarters. The position peaked at $91K in Q2 2020. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- US Bancorp reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- US Bancorp sold 54 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $4K.
- US Bancorp first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 18 quarters.
- US Bancorp's Global Blood Therapeutics, Inc. position peaked at $91K in Q2 2020.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on US Bancorp's 13F filing for Q4 2022, filed 13 Feb 2023.